ProCE Banner Activity

Carfilzomib, Pomalidomide, Dexamethasone Feasible in Patients With Relapsed/Refractory MM

Slideset Download
Conference Coverage
Early-phase data from a single-arm study demonstrate favorable safety and efficacy for the KPd combination in a population of patients with relapsed/refractory MM who were largely refractory to lenalidomide.

Released: June 06, 2016

Expiration: June 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals